1-(3'-hydroxypropyl)piperidin-2-one | 71533-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3'-hydroxypropyl)piperidin-2-one
• 英文别名: N-(3'-hydroxypropyl)piperidone-2；N-(3-hydroxypropyl)valerolactam；1-(3-hydroxy-propyl)-piperidin-2-one；1-(3-Hydroxy-propyl)-piperidon-(2)；3-(2-Oxo-piperidino)-propanol-(1)；1-(3-Hydroxypropyl)piperidin-2-one
• CAS: 71533-22-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: CSXDLVLNYQAYDR-UHFFFAOYSA-N

物化性质

• 沸点：
  155-158 °C(Press: 1.0-1.5 Torr)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3'-hydroxypropyl)piperidin-2-one 生成 9a-(4-methoxy-benzyloxy)-5-methyl-hexahydro-pyrido[2,1-b][1,3]oxazinium; perchlorate
  参考文献：
  名称：

  Syntheses of nine- and ten-membered amino lactones from 1-azabicyclic immonium ether perchlorates

  摘要：

  DOI：

  10.1016/s0040-4039(01)86045-7
• 作为产物：
  描述：

  N-(3-(tetrahydropyranyloxy)propyl)valerolactam 在 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 生成 1-(3'-hydroxypropyl)piperidin-2-one
  参考文献：
  名称：

  Okita, Makoto; Wakamatsu, Takeshi; Mori, Miwako, Heterocycles, 1980, vol. 14, # 8, p. 1089 - 1092

  摘要：

  DOI：

文献信息

• Ring expansion by in situ tethering of hydroxy azides to ketones: The boyer reaction
  作者：Vijaya Gracias、Kristine E. Frank、Gregory L. Milligan、Jeffrey Aubé

  DOI：10.1016/s0040-4020(97)01012-0

  日期：1997.12

  under the action of protic or Lewis acids such as BF3·OEt2. The reaction appears to succeed due to the initial formation of a hemiketal, which then renders the attack of azide on an oxonium ion intramolecular. The scope of this reaction vis à vis ketone and hydroxyalkyl azide structure is discussed.

  尽管叠氮化物可以与酮反应形成扩环的内酰胺，但该反应的通用性差，并且需要使用强力的路易斯酸促进剂。1,2-和1,3-羟烷基叠氮化物与酮的反应在质子酸或路易斯酸（例如BF 3 ·OEt 2）的作用下以高收率生成N-羟烷基内酰胺。由于半缩醛的最初形成，该反应似乎成功，然后使叠氮化物对氧离子离子分子内的侵蚀。讨论了该反应相对于酮和羟烷基叠氮化物结构的范围。
• Fluorene Compound and Pharmaceutical Use Thereof
  申请人：Motomura Takahisa

  公开号：US20100240634A1

  公开（公告）日：2010-09-23

  The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种用于预防或治疗糖尿病、糖尿病并发症、胰岛素抵抗综合征、代谢综合征、高血糖、血脂异常、动脉粥样硬化、心力衰竭、心肌病、心肌缺血、脑缺血、脑卒中、肺动脉高压、高乳酸血症、线粒体疾病、线粒体脑病或癌症的药剂，即PDHK抑制剂等。一种由下式[I]表示的化合物或其药学上可接受的盐，或其溶剂：其中每个符号如规范中所定义。
• Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
  申请人：Himmelsbach Frank

  公开号：US20050182043A1

  公开（公告）日：2005-08-18

  The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.

  本发明涉及一种治疗疾病的方法，所述疾病包括良性或恶性肿瘤、呼吸道和肺部疾病、胆道和胆囊疾病以及胃肠道疾病，通过向需要治疗的患者施用以下一般式的双环杂环基的治疗有效量：其中所述取代基如定义所述。
• Pyrrole derivatives and pharmaceutical compositions which contain them
  申请人：Rhone-Poulenc Sante

  公开号：US04898871A1

  公开（公告）日：1990-02-06

  Pyrrole derivatives of formula ##STR1## in which A forms with the pyrrole ring an isoindoline, 6,7-dihydro-5H-pyrrolo-[3,4-b]pyrazine, 2,3,6,7-tetrahydro-5H-[1,4]-oxathiino-[2,3-c]pyrrole or 2,3,6,7-tetrahydro-5H-[1,4]dithiino-[2,3-c]pyrrole ring-system, Y+0, S or NH, Het=naphthyridinyl or quinolyl which are unsubstituted or substituted with halogen, (1 to 4 C) alkyl, (1 to 4 C) alkyloxy, (1 to 4 C) alkylthio, CN or CF.sub.3 and R=(3 to 10 C) alkenyl or alkyl which is unsubstituted or substituted with alkyloxy, alkylthio, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl or cycloalkylcarbamoyl in which the cycloalkyl portions contain 3 to 6 C, NH.sub.2, alkylamino, dialkylamino, alkylcarbonylamino, 1- or 2-piperazinyl, piperidyl, piperidino, morpholino, 1-azetidinyl, pyrrolidinyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, (1-piperazinyl)carbonyl, piperidinocarbonyl, piperidylcarbonyl, (1-pyrrolidinyl)carbonyl, morpholinocarbonyl, aminoalkylcarbamoyl, alkylaminoalkylcarbamoyl, dialkylaminoalkylcarbamoyl, alkyloxyalkylcarbamoyl, phenyl, pyridyl, or 1-imidazolyl, or R=2- or 3-pyrrolidinyl, or 1-imidazolyl, or 2-, 3- or 4-piperidyl, the aforesaid piperazinyl, piperidino, piperidyl, pyrrolidinyl, and azetidinyl radicals being unsubstituted or substituted at any position by alkyl, OH, alkylcarbonyl, benzyl, or hydroxyalkyl, or can form (i) a lactam group with the nitrogen atom of the ring or (ii) a 2-spirodioxolane residue with a carbon of the ring, and the said alkyl radicals containing 1 to 10 C except where specifically stated, are useful as anxiolytics.

  该文中描述的Pyrrole衍生物的化学式为##STR1##其中A与pyrrole环形成一个isoindoline、6,7-二氢-5H-吡咯并[3,4-b]吡嗪、2,3,6,7-四氢-5H-[1,4]-噁二嗪并[2,3-c]吡咯或2,3,6,7-四氢-5H-[1,4]二噻吩并[2,3-c]吡咯环系统，Y+0，S或NH，Het=naphthyridinyl或quinolyl，它们未被取代或取代了卤素、(1到4C)烷基、(1到4C)烷氧基、(1到4C)烷硫基、CN或CF.sub.3，R=(3到10C)烯丙基或烷基，它们未被取代或取代了烷氧基、烷硫基、环烷基、烷基羰基、环烷基羰基或环烷基氨基酰基，其中环烷基部分含有3到6C，NH.sub.2、烷基氨基、二烷基氨基、烷基羰基氨基、1-或2-哌嗪基、哌啶基、哌啶基、吗啉基、1-氮杂-2-环丙基、吡咯基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、烷氧基烷基甲酰基、苯基、吡啶基或1-咪唑基，或R=2-或3-吡咯基、1-咪唑基、2-、3-或4-哌啶基，上述哌嗪基、哌啶基、哌啶基、吡咯基和氮杂-2-环丙基基团未被取代或在任何位置被烷基、OH、烷基羰基、苄基或羟基烷基替代，或者可以形成(i)与环上的氮原子形成内酰胺基团或(ii)与环上的碳形成2-螺二氧兰残基，所述烷基基团含有1到10个碳，除非特别说明，这些化合物可用作抗焦虑剂。
• BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME
  申请人：HIMMELSBACH Frank

  公开号：US20110077246A1

  公开（公告）日：2011-03-31

  The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.

  本发明涉及治疗疾病的方法，所述疾病包括良性或恶性肿瘤、呼吸道和肺部疾病、胃肠道疾病、胆管和胆囊疾病，通过向需要治疗的患者施用下列一般式的双环杂环基的治疗有效量：其中所述取代基如本文所定义。